Suzhou Chinese Medicine Research Institute

Suzhou Chinese Medicine Research Institute (SCMRI), officially known as Suzhou Institute of Traditional Chinese Medicine Co., Ltd., is a research-focused pharmaceutical company based in Suzhou, China. Established in 1991 as a joint venture between the Hong Kong-based Baicaotang (Winsor Health Products) and Suzhou Medical College (now Soochow University), the institute is a pioneer in the modernization of Traditional Chinese Medicine (TCM). SCMRI focuses on developing innovative TCM therapies for chronic and complex diseases, including cancer, cardiovascular conditions, diabetes, and respiratory ailments. The company has successfully developed several high-profile TCM products, such as the 1.1 class new drugs Bailing Zhike Granules and Qingjiang Hewei Granules, often collaborating with major industry partners like Kangyuan Pharmaceutical and Zhenbaodao Pharmaceutical for commercialization.